| Filed On | Filing |
|---|---|
| 17 Sep 2026 |
8-K: Other Events
Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK® in Japan AT SIOP 2026 |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2026, Fennec Pharmaceuticals Inc. (the “Company”) held an annual meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director... |
| 22 May 2026 |
8-K: Other Events
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ |
| 18 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Research Triangle Park, NC, May 18, 2026 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Compa... |
| 28 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 27, 2026, Rostislav Raykov notified Fennec Pharmaceuticals Inc. (the "Company") of his desire to retire from the Company's Board of Directors (the "Board") and that he will not stand for re-election at the Company's 2026 annual ... |
| 22 Apr 2026 |
8-K: Other Events
– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients – |
| 07 Apr 2026 |
8-K: Other Events
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ |
| 24 Mar 2026 |
8-K: Results of Operations and Financial Condition
~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ |
| 16 Mar 2026 |
8-K: Other Events
Research Triangle Park, NC, March 16, 2026 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle ... |
| 04 Mar 2026 |
8-K: Other Events
–Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid Tumors Receiving Cisp... |
| 20 Feb 2026 |
8-K: Other Events
FENNEC PHARMACEUTICALS PRESENTS REAL WORLD DATA SUPPORTING THE integration AND CLINICAL USE OF Pedmark® IN TREATING ADULTS WITH HEAD & nECK CANCERS |
| 09 Dec 2025 |
8-K: Other Events
FENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED TRIAL to be Conducted by CITY OF HOPE IN Metastatic Testicular Germ Cell Tumors |
| 02 Dec 2025 |
8-K: Other Events
FENNEC PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM INVESTIGATOR-INITIATED CLINICAL STUDY OF PEDMARK® IN JAPAN TO REDUCE CISPLATIN-INDUCED HEARING LOSS |
| 19 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Waiver and Redemption Agreement, dated as of November 13, 2025 (this “Agreement”), is entered into by and among Fennec Pharmaceuticals Inc., a British Columbia corporation (the “Company”), the investors party hereto (the “Investors”... |
| 18 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
THIS OFFERING DOCUMENT DOES NOT CONSTITUTE AN OFFER TO SELL, OR THE SOLICITATION OF AN OFFER TO BUY, ANY OF THE SECURITIES DESCRIBED HEREIN WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY U.S. PERSON OR OTHER PERSON... |
| 17 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Fennec Pharmaceuticals Inc., a British Columbia corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,666,667 of its common shares, no par value per... |
| 03 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 3, 2025, Fennec Pharmaceuticals Inc. (the “Company”) held an annual meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director,... |
| 10 Mar 2025 |
8-K: Results of Operations and Financial Condition
~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ |
| 07 Feb 2025 |
8-K: Other Events
~ PEDMARQSI Ò is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with Localized, Non-Metastatic Solid Tu... |
| 20 Dec 2024 |
8-K: Other Events
FENNEC PHARMACEUTICALS ANNOUNCES PEDMARQSIÒ POSITIVE RECOMMENDATION BY NICE FOR THE PREVENTION OF CISPLATIN-INDUCED HEARING LOSS IN ENGLAND AND WALES |
Loading...